Robert M. Wasserman, Director of Research
Mr. Wasserman has over twenty five years of experience in equity research, specializing in the area of health care with a unique focus on companies in the Southeastern US and Florida . Among the areas Mr. Wasserman has covered are pharmaceuticals, medical devices, healthcare services and biotechnology. Mr. Wasserman has analyzed and written on over 100 publicly traded health care companies. Mr. Wasserman was the founder of the Research effort at Dawson James, and he has also served as Director of Research for Jesup & Lamont, Senior Research Analyst for Craig-Hallum Capital Group and Vice President-Research and Partner for Southeast Research Partners/Ryan Beck. Prior to entering the securities industry, Mr. Wasserman was a management consultant with Peat, Marwick, Mitchell & Co., now KPMG Peat Marwick.
Mr. Wasserman was selected All-Star Healthcare analyst for 2000 by the Wall Street Journal, and has appeared in a number of media outlets, including Business Week, Forbes, The New York Times and CNBC.
Mr. Wasserman received his Masters of Business Administration degree in Finance from the University of Chicago and dual Bachelor of Science degrees in Management and Engineering from the Massachusetts Institute of Technology.
Barry M. Sine, Managing Director, Equity Research
Barry Sine is a veteran wall street equity analyst focused on Technology, Media and Telecommunications (TMT). Mr. Sine previously founded and built a ten-analyst research department at Drexel Hamilton and was formerly Director of Research and Senior Telecom Analyst at CapStone Investments. Mr. Sine also held positions as a Generalist Senior Analyst at Oppenheimer, HD Brous & Co., Inc and as a financial consultant with AT&T.
Mr. Sine received a Number 2 Wall Street Analyst Ranking in 2017 and the Number 1 ranking in 2013 by the Financial Times in US Telecom Services and is a frequent on-air contributor on both CNBC and Bloomberg TV.
Mr. Sine received his M.B.A. Finance/International Business from NYU, Leonard N. Stern School of Business and Bachelor of Science degree in Economics/Finance from Fairleigh Dickinson University. Mr. Sine holds FINRA licenses Series 7, 16,24,63,86 and 87.
Carol Ann Werther, Managing Director, Life Sciences Research Analyst
Ms. Werther has over 20 years’ experience covering the biotechnology and specialty pharmaceutical sectors. She most recently was a Managing Director at H.C. Wainwright focused on orphan disease, RNAi therapeutics, and gene therapy companies. Previously, she held sell side positions at CRT Capital, Summer Street Research Partners, Think Equity Partners, Adams, Harkness and Hill, and Cowen & Company. Ms. Werther built a four-person biotechnology practice at Adams Harkness & Hill that now is part of Canaccord Genuity. She has been recognized in Tip Ranks, Reuters Industry Survey, the Wall Street Journal and in Greenwich. In addition, she held portfolio managerial positions for the healthcare sector funds at INVESCO Trust Company and at Rothschild Asset Management.
Ms. Werther received her M.B.A. in Finance from NYU, Leonard N. Stern School of Business. She has a M.S. in Clinical Nutrition Sciences from the University of Alabama in Birmingham and a B.S. in Nutritional Sciences from Cornell University. She is a Registered Dietitian.